Treprostinil (Remodulin) vs Treprostinil (Tyvaso)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Pulmonary Arterial Hypertension

Shared mechanism: IP receptor (prostacyclin pathway) · full Pulmonary Arterial Hypertension pipeline

Treprostinil (Remodulin)

Marketed by United Therapeutics

Approved in Pulmonary Arterial Hypertensionsmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: June 2027 · NCT06317805 (registry estimate)

No aligned efficacy figure on record for this race.

Treprostinil (Tyvaso)

Marketed by United Therapeutics

Approved in Pulmonary Arterial Hypertensionsmall molecule
Reliable signal

NCT00147199 · Phase 3 · completed

This was a randomized, quadruple-blind, placebo-controlled trial of 235 participants, with 115 receiving inhaled treprostinil and 120 receiving placebo. The prespecified clinical primary endpoint—change in peak 6-minute walk distance at Week 12—was met, with a between-group estimate of 20.0 meters (95% CI 8.0–32.8; p=0.00044).

Next expected readout: December 2027 · NCT07177703 (registry estimate)

Reported efficacy

Peak 6-minute Walk Distance (12 weeks): Peak 6-minute Walk Distance (12 weeks): Inhaled Treprostinil — Week 12: 366 meters (IQR 300 to 423); Change from Baseline: 21.6 meters (IQR -8 to 54) vs Placebo — Week 12: 360 meters (IQR 296 to 414.9); Change from Baseline: 3 meters (IQR -26 to 31.5) (met)

Result source: NCT00147199

Results for Pulmonary Arterial Hypertension

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Coverage. Treprostinil (Remodulin): 4 of 5 rows · Treprostinil (Tyvaso): 5 of 5 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricTreprostinil (Remodulin)Treprostinil (Tyvaso)
6MWD - Change
absolute change · m
No placebo or comparator arm
440.8 ma,b,c
NCT03055221 · Phase 4 · registry result, not featured evidence
20 m @ 12wka,b,c
NCT01268553 · Phase 4 · registry result, not featured evidence
1 other source trial
230 m @ 12wk
NCT00705133 · Phase 2 · registry result, not featured evidence
Dropout rate
n/a: no completion milestoned
NCT03055221 · Phase 4 · registry result, not featured evidence
11.3%e
NCT00147199 · Phase 3 · monotherapy · Hypertension, Pulmonary Arterial Hypertension · phase 3
show 3 more results
0%
NCT01268553 · Phase 4 · registry result, not featured evidence
11%
NCT00741819 · Phase 4 · registry result, not featured evidence
0%
NCT00705133 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
10%d
NCT03055221 · Phase 4 · registry result, not featured evidence
—e
NCT00147199 · Phase 3 · monotherapy · Hypertension, Pulmonary Arterial Hypertension · phase 3
show 3 more results
—
NCT01268553 · Phase 4 · registry result, not featured evidence
4.1%
NCT00741819 · Phase 4 · registry result, not featured evidence
—
NCT00705133 · Phase 2 · registry result, not featured evidence
Serious AEs
87.5%d
NCT03055221 · Phase 4 · registry result, not featured evidence
7.8%e
NCT00147199 · Phase 3 · monotherapy · Hypertension, Pulmonary Arterial Hypertension · phase 3
show 3 more results
0%
NCT01268553 · Phase 4 · registry result, not featured evidence
13.7%
NCT00741819 · Phase 4 · registry result, not featured evidence
0%
NCT00705133 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
d
abdominal discomfort 18.8%
catheter site pain 18.8%
cough 18.8%
NCT03055221 · Phase 4 · registry result, not featured evidence
e
cough 53.9% (placebo 29.2%)
headache 40.9% (placebo 22.5%)
nausea 19.1% (placebo 10.8%)
NCT00147199 · Phase 3 · monotherapy · Hypertension, Pulmonary Arterial Hypertension · phase 3
show 2 more results
cough 74%
headache 43.8%
nausea 30.1%
NCT00741819 · Phase 4 · registry result, not featured evidence
general prostacyclin adverse reaction profile 100%
NCT00705133 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation context differs: registered conditions differ.
  2. bTreatment context has not been resolved for both arms.
  3. cThe assessment timepoint is not available for both results.
  4. dPopulation comparability has not been reviewed for these studies.
  5. ePopulation comparability has not been reviewed for 3 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Treprostinil (Remodulin)

NYHA Class 2.1 Functional Class
absolute change · Functional Class
No placebo or comparator arm
NCT03055221 · Phase 4 · registry result, not featured evidence

Treprostinil (Tyvaso)

Six Minute Walk Distance Peak Change 21.6 vs 3 placebo m @ 12wk
absolute change · m
Change from Baseline
NCT00147199 · Phase 3 · monotherapy · Hypertension, Pulmonary Arterial Hypertension · phase 3
show 1 more result
21.6 vs 3 placebo m @ 6wk
Change from Baseline
NCT00147199 · Phase 3 · monotherapy · Hypertension, Pulmonary Arterial Hypertension · phase 3
Clinical Worsening 4 vs 6 placebo count @ 12wk
event rate · count
NCT00147199 · Phase 3 · monotherapy · Hypertension, Pulmonary Arterial Hypertension · phase 3
Borg Dyspnea 0 vs 0 placebo score @ 12wk
absolute change · score
Change from Baseline
NCT00147199 · Phase 3 · monotherapy · Hypertension, Pulmonary Arterial Hypertension · phase 3
Six Minute Walk Distance Trough Change 12.4 vs 0.8 placebo m @ 12wk
absolute change · m
Change from Baseline
NCT00147199 · Phase 3 · monotherapy · Hypertension, Pulmonary Arterial Hypertension · phase 3
Mlwhf Total -3 vs 0 placebo score @ 12wk
absolute change · score
Global Score
NCT00147199 · Phase 3 · monotherapy · Hypertension, Pulmonary Arterial Hypertension · phase 3
Signs and Symptoms 0 vs 0 placebo score @ 12wk
absolute change · score
NCT00147199 · Phase 3 · monotherapy · Hypertension, Pulmonary Arterial Hypertension · phase 3
Clinical Worsening Free 100% (n=6) @ 12wk
event count · % of participants
No placebo or comparator arm
NCT01268553 · Phase 4 · registry result, not featured evidence · converted to % from 6 Participants as posted
Ventilatory Efficiency Change Slope 1.2 ratio @ 12wk
ratio to baseline · ratio
No placebo or comparator arm
NCT01268553 · Phase 4 · registry result, not featured evidence
CAMPHOR -0.5 score @ 12wk
absolute change · score
No placebo or comparator arm
NCT01268553 · Phase 4 · registry result, not featured evidence
6MWD - Change 16 m @ 12wk
absolute change · m
No placebo or comparator arm
Change from Baseline
NCT00741819 · Phase 4 · registry result, not featured evidence
QOL -2.4 score @ 12wk
absolute change · score
No placebo or comparator arm
Change in Quality of Life Score
NCT00741819 · Phase 4 · registry result, not featured evidence
CAMPHOR -6.4 score @ 12wk
absolute change · score
No placebo or comparator arm
Change in Total Score
NCT00741819 · Phase 4 · registry result, not featured evidence

+ 2 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Treprostinil (Remodulin)'s landscape · Treprostinil (Tyvaso)'s landscape